



1 facilitate the cost-effective purchase of a case-managed  
2 continuum of care. The agency shall also require providers to  
3 minimize the exposure of recipients to the need for acute  
4 inpatient, custodial, and other institutional care and the  
5 inappropriate or unnecessary use of high-cost services. The  
6 agency shall contract with a vendor to monitor and evaluate  
7 the clinical practice patterns of providers in order to  
8 identify trends that are outside the normal practice patterns  
9 of a provider's professional peers or the national guidelines  
10 of a provider's professional association. The vendor must be  
11 able to provide information and counseling to a provider whose  
12 practice patterns are outside the norms, in consultation with  
13 the agency, to improve patient care and reduce inappropriate  
14 utilization. The agency may mandate prior authorization, drug  
15 therapy management, or disease management participation for  
16 certain populations of Medicaid beneficiaries, certain drug  
17 classes, or particular drugs to prevent fraud, abuse, overuse,  
18 and possible dangerous drug interactions. The Pharmaceutical  
19 and Therapeutics Committee shall make recommendations to the  
20 agency on drugs for which prior authorization is required. The  
21 agency shall inform the Pharmaceutical and Therapeutics  
22 Committee of its decisions regarding drugs subject to prior  
23 authorization. The agency is authorized to limit the entities  
24 it contracts with or enrolls as Medicaid providers by  
25 developing a provider network through provider credentialing.  
26 The agency may competitively bid single-source-provider  
27 contracts if procurement of goods or services results in  
28 demonstrated cost savings to the state without limiting access  
29 to care. The agency may limit its network based on the  
30 assessment of beneficiary access to care, provider  
31 availability, provider quality standards, time and distance

1 standards for access to care, the cultural competence of the  
2 provider network, demographic characteristics of Medicaid  
3 beneficiaries, practice and provider-to-beneficiary standards,  
4 appointment wait times, beneficiary use of services, provider  
5 turnover, provider profiling, provider licensure history,  
6 previous program integrity investigations and findings, peer  
7 review, provider Medicaid policy and billing compliance  
8 records, clinical and medical record audits, and other  
9 factors. Providers shall not be entitled to enrollment in the  
10 Medicaid provider network. The agency shall determine  
11 instances in which allowing Medicaid beneficiaries to purchase  
12 durable medical equipment and other goods is less expensive to  
13 the Medicaid program than long-term rental of the equipment or  
14 goods. The agency may establish rules to facilitate purchases  
15 in lieu of long-term rentals in order to protect against fraud  
16 and abuse in the Medicaid program as defined in s. 409.913.  
17 The agency may seek federal waivers necessary to administer  
18 these policies.

19 (51) The agency shall work with the Agency for Persons  
20 with Disabilities to develop a ~~model~~ home and community-based  
21 waiver to serve children and adults who are diagnosed with  
22 familial dysautonomia or Riley-Day syndrome caused by a  
23 mutation of the IKBKAP gene on chromosome 9. The agency shall  
24 seek federal waiver approval and implement the approved waiver  
25 ~~subject to the availability of funds and any limitations~~  
26 ~~provided~~ in the General Appropriations Act. The agency may  
27 adopt rules to implement this waiver program.

28 Section 2. The sums of \$171,840 from the General  
29 Revenue Fund and \$246,160 from the Medical Care Trust Fund are  
30 appropriated to the Agency for Health Care Administration for  
31

